Related Experiment Videos
Possible nizatidine-induced subfulminant hepatic failure
W D Chey1, M L Kochman, P G Traber
1Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, USA.
Journal of Clinical Gastroenterology
|March 1, 1995
Summary
Nizatidine, a histamine-2 receptor antagonist, may potentially cause subfulminant hepatic failure. This rare adverse event can progress to cirrhosis, highlighting the need for vigilance in patients taking this medication.
Area of Science:
- Hepatology
- Pharmacology
- Gastroenterology
Background:
- Histamine-2 receptor antagonists are commonly prescribed for acid-related gastrointestinal disorders.
- Subfulminant hepatic failure is a rare but severe liver condition.
- Previous literature has not established a link between histamine-2 receptor antagonists and subfulminant hepatic failure.
Observation:
- A case of subfulminant hepatic failure is presented in a patient treated with nizatidine.
- The patient's liver condition progressed despite treatment, eventually leading to cirrhosis.
Findings:
- This case suggests a potential association between nizatidine use and the development of subfulminant hepatic failure.
- Nizatidine-induced liver injury may represent a rare idiosyncratic reaction.
Implications:
- Clinicians should consider nizatidine as a potential cause of subfulminant hepatic failure in patients presenting with acute liver injury.
- Further investigation into the safety profile of histamine-2 receptor antagonists is warranted.
- Early recognition and withdrawal of the offending agent may be crucial in managing potential nizatidine-induced liver injury.